A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080 - Wikidata - wikimedia - TriplyDB

A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080

A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080

http://www.wikidata.org/entity/Q34063604

about

Pharmacodynamic modeling of adverse effects of anti-cancer drug treatment A Review of Modeling Approaches to Predict Drug Response in Clinical Oncology Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancer Pharmacodynamic models for discrete data.Sorafenib dose escalation is not uniformly associated with blood pressure elevations in normotensive patients with advanced malignancies.Safety and efficacy profile of lenvatinib in cancer therapy: a systematic review and meta-analysis Population pharmacokinetic-pharmacodynamic modelling in oncology: a tool for predicting clinical response.Medullary thyroid carcinoma: molecular signaling pathways and emerging therapies Simultaneous Exposure-Response Modeling of ACR20, ACR50, and ACR70 Improvement Scores in Rheumatoid Arthritis Patients Treated With Certolizumab Pegol.A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine-refractory differentiated thyroid cancer Model-based treatment optimization of a novel VEGFR inhibitor.Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma.PKPD Modeling of Predictors for Adverse Effects and Overall Survival in Sunitinib-Treated Patients With GIST.FGF receptor inhibitors: role in cancer therapy.Novel therapies for thyroid cancer.Bringing Model-Based Prediction to Oncology Clinical Practice: A Review of Pharmacometrics Principles and Applications.Drug safety evaluation of lenvatinib for thyroid cancer.Lenvatinib: a new option for the treatment of advanced iodine refractory differentiated thyroid cancer?Clinical features of lenvatinib treatment in elderly patients with advanced thyroid cancer.Successful recovery from a subclavicular ulcer caused by lenvatinib for thyroid cancer: a case report.Population pharmacokinetic-pharmacodynamic modelling of 24-h diastolic ambulatory blood pressure changes mediated by axitinib in patients with metastatic renal cell carcinoma.Mathematical modeling identifies optimum lapatinib dosing schedules for the treatment of glioblastoma patients.Mathematical modeling of efficacy and safety for anticancer drugs clinical development.Posterior Reversible Encephalopathy Syndrome after Lenvatinib Therapy in a Patient with Anaplastic Thyroid Carcinoma.Pharmacokinetics and excretion of (14)C-lenvatinib in patients with advanced solid tumors or lymphomas.

P2860

Q26766318-8DB3A4D7-6BA1-46C2-B301-D0DD0364FEAE Q28066777-E532DEE6-F581-4F3D-BE78-50D47013E38E Q28072655-5F8467C8-97C3-473B-A1A3-CE94F2AD98D0 Q30578472-30491513-DE19-425C-A7F3-0956A6FE0C1C Q30587082-338F9BC9-9243-41C4-A664-EED3A8769AC3 Q33433315-8F835A46-A8EC-470F-9287-2A747F5DDAB9 Q34953673-543AE492-CE5F-4328-B24A-BC76B24FA0DB Q35038893-BA177834-B6D5-40ED-84C3-5F1273DF1488 Q35760130-4F533038-C803-4B45-850C-602772F104E6 Q35949539-D68950CD-0D12-4727-9160-A60825EAF98A Q36467394-8F20243F-149E-4BA4-AA41-E7C2B76019B2 Q36779136-69332FCA-62C8-415B-AB54-CA9BAAC3FF20 Q36825455-57CFADAD-38D9-4377-9493-F706B47139DF Q37405613-6857BEB0-ACA3-4633-8FDA-D3AEB994646E Q37981986-26839AB4-CDDA-4639-876A-E6A15100C17A Q38260495-80710551-155B-458C-B66A-1DE8C3E8DBB1 Q38289581-8797F938-E074-4081-AB99-5AE004EDD466 Q38612008-3592D55A-35AA-4C80-B40B-62EC23168895 Q38995525-56B6C175-6353-4055-83DC-007AFEB615E4 Q40990450-289308DC-5125-46DE-BF93-F347E4DC36D4 Q42330302-0582EF55-5824-4AFF-9911-9723687FB7B7 Q43939236-F7AF1FA0-9602-4EF6-B5F2-7DD4B252225D Q47569610-66EFC905-78F0-4992-AA00-6CC417CB5E9A Q47663303-8FD0CF27-B987-42D9-9864-71CE8560D865 Q47923729-563D700E-5F93-4D30-8BA1-7869F186162F Q54311105-65A4CB51-CFFE-4CF3-8291-FE3E49F17F05

P2860

A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080

http://www.wikidata.org/entity/Q34063604

description

2010 nî lūn-bûn

@nan

2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

A model of hypertension and pr ...... the anti-angiogenic drug E7080

@ast

A model of hypertension and pr ...... the anti-angiogenic drug E7080

@en

A model of hypertension and pr ...... the anti-angiogenic drug E7080

@nl

type

label

A model of hypertension and pr ...... the anti-angiogenic drug E7080

@ast

A model of hypertension and pr ...... the anti-angiogenic drug E7080

@en

A model of hypertension and pr ...... the anti-angiogenic drug E7080

@nl

prefLabel

A model of hypertension and pr ...... the anti-angiogenic drug E7080

@ast

A model of hypertension and pr ...... the anti-angiogenic drug E7080

@en

A model of hypertension and pr ...... the anti-angiogenic drug E7080

@nl

P1433

Q34063604-F432DCDB-96DC-45A5-92DF-34F3E5892389

P1476

Q34063604-8ADBC8D2-1BF2-4A49-96CE-492D72F43CFC

P2093

Q34063604-0931A28E-57F1-4FAA-8687-5BAC71C9510C

Q34063604-1ADBCC27-A874-423D-9735-6BA4A441D713

Q34063604-4179222E-8FFC-44BC-B0DF-E7230B41BC17

Q34063604-642BD30E-34AC-457D-86C7-D57B72B71FC6

Q34063604-72764C01-09CC-4FD6-B347-2E9333C3247E

Q34063604-ABE472A2-5440-4F8D-92C6-0F4C529EA626

Q34063604-D441BF0A-18BC-4916-8613-BD43C5D4B831

Q34063604-E3C2A3B6-B189-4DE4-B6A6-2B0C565B9FFD

Q34063604-E5EBAA44-DC70-4750-BA32-B6396EFD76B6

P2860

Q34063604-0FE68D0C-C986-43C2-AECD-C7A06D71250E

Q34063604-170DE226-743F-49B2-BB56-FA4CDC11713A

Q34063604-1F9B31B4-D9CB-46B1-BB60-2711F1B9347A

Q34063604-25E42CC7-6431-4FC9-9CAC-FE2E7DE902C7

Q34063604-2F6B79AD-2EB0-448E-9389-AD2584438B4A

Q34063604-3BC60053-9567-4D53-B61B-CDB0CE93B6B9

Q34063604-3CCCA03C-7510-413A-9BDF-558EDF8F9214

Q34063604-3E87EE6E-3A35-4F2F-9AC6-118E0EC59ABC

Q34063604-6AD9B3D2-BE28-454A-BD93-4699B368BFCA

Q34063604-6EB69596-75B3-4A5A-997E-81BE91741748

P2888

Q34063604-808DE653-03F4-4A5A-955D-DF6472CDAB07

P304

Q34063604-F5469404-FF87-441F-A51F-C97FF2006A3A

P31

Q34063604-7A94A575-7F5A-4221-A271-D49E8892391E

P356

Q34063604-CC5607C3-CA57-4627-9308-A104BF8F317E

P433

Q34063604-10B513D9-7DA3-4BC3-BF6F-C766AFCF9401

P478

Q34063604-3E9AD28F-9A01-4B50-93A1-B48D02CD8E13

P577

Q34063604-9B44F64D-D1D0-4458-9F6C-B69CFE21FFBE

P5875

Q34063604-AEA44F28-AB7C-4EF4-BC97-B10C51181AA9

P6179

Q34063604-D2066142-1CA7-4A00-9239-C26F00FF65AF

P698

Q34063604-60A4694D-10F3-43F3-B4A3-A444CBA2EA9A

P921

Q34063604-9F608D38-D524-4F7E-9344-E4E823B5D1AD

P932

Q34063604-40F12208-E8C2-4D83-A651-892ED6703E8B

P356

S10928-010-9164-2

P1433

Journal of Pharmacokinetics and Pharmacodynamics

P1476

A model of hypertension and pr ...... the anti-angiogenic drug E7080

@en

P2093

Alwin D R Huitema

http://www.w3.org/2001/XMLSchema#string

Anubha Gupta

http://www.w3.org/2001/XMLSchema#string

Jan H M Schellens

http://www.w3.org/2001/XMLSchema#string

Jantien Wanders

http://www.w3.org/2001/XMLSchema#string

Jos H Beijnen

http://www.w3.org/2001/XMLSchema#string

Mats O Karlsson

http://www.w3.org/2001/XMLSchema#string

Melvin R Mac Gillavry

http://www.w3.org/2001/XMLSchema#string

Mendel Jansen

http://www.w3.org/2001/XMLSchema#string

Ron J Keizer

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study

Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data.

PsN-Toolkit--a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM.

Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor.

Comparison of four basic models of indirect pharmacodynamic responses

Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase.

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.

The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review.

Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis.

Prevalence, concentration, and prognostic importance of proteinuria in patients with malignancies.

P2888

s10928-010-9164-2

P304

347-363

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10928-010-9164-2

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

37

http://www.w3.org/2001/XMLSchema#string

P577

2010-07-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45283688

http://www.w3.org/2001/XMLSchema#string

P6179

1041046109

http://www.w3.org/2001/XMLSchema#string

P698

20652729

http://www.w3.org/2001/XMLSchema#string

P921

P932

2921067

http://www.w3.org/2001/XMLSchema#string